
“Dual targeting of chemoresistance and ferroptosis in gastric cancer: DDR1/VEGFR2 inhibitor K-13 synergizes with docetaxel from preclinical models to phase Ib/II clinical trial”
A promising therapeutic strategy for late-stage GC patients ⤵️
nature.com/articles/s4141…


English




















